Mike Sharma: Adding Antiplatelets to Anticoagulation in AF Increases Harm Without Benefit
Mike Sharma, Senior Scientist at Population Health Research Institute, reposted from JAMA Neurology on LinkedIn:
”Adding antiplatelets to anticoagulation in the setting of AF results in hazard without benefit. Now we’ll established in multiple studies. Where we lack data is in short term use following a cerebrovascular event that may be atherosclerotic in origin in patients with coexisting AF.”
Quoting JAMA Neurology‘s post:
”Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events.”
Read the full article here.
Title: Anticoagulation and Antiplatelet Therapy in Patients With Atrial Fibrillation and Atherosclerosis
Authors: Richard A. Bernstein, Lauren E. Previch
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show